Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 580-589 |
| Number of pages | 10 |
| Journal | Nature Clinical Practice Rheumatology |
| Volume | 3 |
| Issue number | 10 |
| DOIs | |
| Publication status | Published - 2007 |
| Externally published | Yes |
Fingerprint
Cite this
}
Primer: genomic and proteomic tools for the molecular dissection of disease. / Walker, Erin; Siminovitch, Katherine.
In: Nature Clinical Practice Rheumatology, Vol. 3, No. 10, 2007, p. 580-589.Research output: Contribution to journal › Article
TY - JOUR
T1 - Primer: genomic and proteomic tools for the molecular dissection of disease
AU - Walker, Erin
AU - Siminovitch, Katherine
PY - 2007
Y1 - 2007
N2 - Completion of the Human Genome Project has been rapidly followed by the emergence of high-throughput technologies that combine automation, miniaturization, and many other strategies and tools to enable systematic surveys of genome composition and gene expression. Of particular relevance to the prevention and management of disease are technologies such as high-throughput DNA genotyping, microarray-based gene-expression profiling, and mass spectrometry-facilitated protein profiling—platforms that collectively support the comprehensive analysis of DNA sequence variants across the genome and the global gene and protein expression changes that distinguish health from disease. Now used extensively in all facets of biomedical investigation, genomic and proteomic tools are already beginning to pinpoint molecular variants that influence risk and outcome in common diseases, and to thereby inform and direct development of novel molecular biomarkers and drug targets. As evidenced by recent advances in DNA sequencing methods, continued improvements in the scope, power, and cost efficiency of genomic and proteomic technologies should ensure their capacity to provide the scale and depth of knowledge required for translating genome sequence information into major medical impact.
AB - Completion of the Human Genome Project has been rapidly followed by the emergence of high-throughput technologies that combine automation, miniaturization, and many other strategies and tools to enable systematic surveys of genome composition and gene expression. Of particular relevance to the prevention and management of disease are technologies such as high-throughput DNA genotyping, microarray-based gene-expression profiling, and mass spectrometry-facilitated protein profiling—platforms that collectively support the comprehensive analysis of DNA sequence variants across the genome and the global gene and protein expression changes that distinguish health from disease. Now used extensively in all facets of biomedical investigation, genomic and proteomic tools are already beginning to pinpoint molecular variants that influence risk and outcome in common diseases, and to thereby inform and direct development of novel molecular biomarkers and drug targets. As evidenced by recent advances in DNA sequencing methods, continued improvements in the scope, power, and cost efficiency of genomic and proteomic technologies should ensure their capacity to provide the scale and depth of knowledge required for translating genome sequence information into major medical impact.
U2 - 10.1038/ncprheum0595
DO - 10.1038/ncprheum0595
M3 - Article
VL - 3
SP - 580
EP - 589
JO - Nature reviews. Rheumatology
JF - Nature reviews. Rheumatology
SN - 1745-8382
IS - 10
ER -